General Anesthesia Versus Spinal Anesthesia in Patients of HELLP Syndrome

Status Completed

Clinical Trial Summary

Anesthesia for caesarian section in patients with HELLP syndrome is a challenge. Measures should be taken during caesarian delivery to guard against the maternal and fetal complications associated with HELLP syndrome.

Clinical Trial Description

The choice of anesthesia for caesarian section in parturient with HELLP syndrome is a debate. The low platelet count, associated with HELLP syndrome, has often favored the choice of general anesthesia for the caesarian delivery of these parturient. However, general anesthesia in such cases; is not a risk-free approach. General anesthesia is associated with increased risk of difficult airways, stress response to intubation and aspiration. It is also thought to have an effect on the fetus with the potential placental transfer of inhalational anesthetics prior to delivery.

Regional anesthesia is widely regarded as a means of providing analgesia for cesarean section.it also avoids the above-mentioned risks associated with general anesthesia. Regional anesthesia for caesarian section in patients with HELLP syndrome has been used by some researchers in many centers with encouraging results.

The lowest platelet count at which one can safely administer neuraxial anesthesia for labour and delivery is controversial. Published studies are few and sample sizes small.

Criteria developed at the University of Mississippi, as of 2006: "For a patient to merit a diagnosis of HELLP syndrome, class 1 requires severe thrombocytopenia (platelets ≤50,000/μl), evidence of hepatic dysfunction (AST and/or ALT ≥70 IU/l), and evidence suggestive of hemolysis (total serum LDH ≥600 IU/l); class 2 requires similar criteria except thrombocytopenia is moderate (>50,000 to ≤100,000/μl); and class 3 includes patients with mild thrombocytopenia (platelets >100,000 but ≤150,000/μl), mild hepatic dysfunction (AST and/or ALT ≥40 IU/l), and hemolysis (total serum LDH ≥600 IU/L).

The researchers chose to investigate class 2 HELLP syndrome as class 3 proved to be safe with regional anesthesia while class 1 seemed to be high risk and un-ethical to do spinal anesthesia with very low platelets count with lack of any evidence to its safety. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03111446
Study type	Interventional
Source	Assiut University
Contact
Status	Completed
Phase	N/A
Start date	April 15, 2017
Completion date	January 1, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Completed	`NCT02911701` - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features	Phase 4
Recruiting	`NCT02247297` - Pancreatic Stone Protein (PSP) in Pregnant Women
Terminated	`NCT04725812` - Complement Regulation to Undo Systemic Harm in Preeclampsia	Phase 2
Recruiting	`NCT06377878` - The Preeclampsia Registry
Recruiting	`NCT02020174` - The Preeclampsia Registry
Recruiting	`NCT02920593` - A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy	Phase 4
Recruiting	`NCT01138839` - Dexamethasone Efficacy in HELLP I Syndrome	Phase 3
Recruiting	`NCT05500989` - PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis
Completed	`NCT04216706` - Early Vascular Adjustments to Prevent Preeclampsia
Recruiting	`NCT03834285` - Liver Disease in Pregnancy
Completed	`NCT00000534` - Calcium for Pre-Eclampsia Prevention (CPEP)	Phase 3
Recruiting	`NCT02807324` - Women Specific Cardiac Recovery After Preeclampsia
Completed	`NCT01736826` - Free DNA and Nucleosome Concentrations in Pathological Pregnancies
Terminated	`NCT00711841` - Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome	Phase 4
Completed	`NCT00097110` - RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil	Phase 3
Completed	`NCT03715647` - Correlation of Survival in Puerperae by Electrical Impedance Tomography
Completed	`NCT03455387` - Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.
Completed	`NCT03232359` - Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome of HELLP Syndrome	N/A
Completed	`NCT03246542` - Promising Bimarker Prediction of Outcome of HELLP Syndrome.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.